IONIS PHARMACEUTICALS INC. news, videos and press releases - Page 4
For more news please use our advanced search feature.
IONIS PHARMACEUTICALS INC. - More news...
IONIS PHARMACEUTICALS INC. - More news...
- Ionis to present at upcoming investor conferences
- Ionis reports fourth quarter and full year 2022 financial results
- Ionis announces new donidalorsen data and presentations at the 2023 American Academy of Allergy, Asthma & Immunology Annual Meeting
- Ionis to hold fourth quarter and full year 2022 financial results webcast
- Ionis announces GSK has advanced bepirovirsen into Phase 3 development
- Ionis receives FDA Fast Track designation for olezarsen in patients with familial chylomicronemia syndrome
- Ionis Chief Scientific Officer C. Frank Bennett, Ph.D. to receive Rainwater Prize for Outstanding Innovation in Neurodegenerative Disease Research
- Ionis and Royalty Pharma enter into royalty agreement for up to $1.1 billion to further advance Ionis' genetic medicines and commercial readiness
- Ionis to present at 41st Annual J.P. Morgan Healthcare conference
- Ionis announces European Medicines Agency accepts Marketing Authorization Application of tofersen to treat rare, genetic form of ALS
- Ionis partners with Metagenomi to add gene editing to its broad technology platform
- Ionis presents positive Phase 2 data from open label extension study of donidalorsen at 2022 ACAAI Annual Meeting
- Ionis to present at upcoming investor conferences
- Ionis reports third quarter financial results
- Ionis announces positive data from GSK's Phase 2b clinical study of bepirovirsen
- Ionis presents positive Phase 2 data in patients with IgA Nephropathy at American Society of Nephrology's Kidney Week 2022
- Ionis announces positive results from fesomersen development program
- Ionis to hold third quarter 2022 financial results webcast
- Ionis announces plan for new manufacturing facility in Oceanside, Calif.
- Ionis provides update on development program evaluating PCSK9 antisense medicine for the treatment of hypercholesterolemia
- Ionis presents positive results from Phase 3 NEURO-TTRansform study at International Symposium on Amyloidosis
- Ionis to present at upcoming investor conferences
- Ionis reports second quarter financial results and recent business achievements
- Ionis announces positive topline results from Phase 2b clinical study of fesomersen, a potential novel anti-thrombotic treatment
- Ionis to hold second quarter 2022 financial results webcast
- Ionis announces that FDA accepts New Drug Application and grants Priority Review of tofersen for a rare, genetic form of ALS
- Ionis announces enrollment completion of Phase 3 Lp(a) HORIZON cardiovascular outcomes study of pelacarsen
- Ionis to participate in virtual fireside chat at H.C. Wainwright 1st Annual Hereditary Angioedema Conference
- Ionis partner licenses rare kidney disease treatment and will advance into Phase 3 clinical study
- Ionis announces presentation of positive Phase 2b data for chronic hepatitis B treatment at the EASL International Liver Congress™
